Psoriatic arthritis

Despite increased awareness and better diagnostic modalities at hand, early diagnosis of psoriatic arthritis (PsA) still remains a huge unmet need. Broad spectrum of PsA manifestations, often gradual and subtle symptom development, along with lack of specific serological testing contributes to the challenge. 

Results of the MAXIMISE trial show that Secukinumab provided clinical improvement and reduction in inflammatory MRI lesions in patients with psoriatic arthritis and axial disease through week 52. 

Early diagnosis of arthritis improves outcomes and quality of life in patients with psoriasis. A longitudinal cohort study shows that the development of PsA within clinically meaningful time frames can be predicted with reasonable accuracy for psoriasis patients.

Each pharmaceutical company has spent months and years preparing to present and highlight their featured clinical trials and abstracts at ACR 2020.  This is our selection of their best studies for you to review and evaluate as part of your to-do list.

Here is the last of our QD Clinics in Podcast form, just before we start ACR2020 coverage. In this compilation from the past week we talk about - HIV and arthritis - Hyperuricemia in PsA - An odd kind of dermatomyositis - Running out of options in Difficult RA Listen here or on your podcast program in your car.

The risk of serious infections (SIE) in RA patients given anti-TNF (TNFi) therapy is not static, instead it has been shown to be greatest in the first 6 months of use according to a recent report in Rheumatology.